Chemotherapeutic gemcitabine doublets in pancreatic carcinoma

Seminars in Oncology

Volumn 32, Issue SUPPL. 6, 2005, Pages

  Richards, Donald A ^a,b  

^a Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

^b Tyler Cancer Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DNA TOPOISOMERASE INHIBITOR; EXATECAN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; LOW MOLECULAR WEIGHT HEPARIN; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; OXALIPLATIN; PEMETREXED; PROTEIN FARNESYLTRANSFERASE INHIBITOR; TIPIFARNIB;

ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; HUMAN; NEUTROPENIA; PANCREAS CARCINOMA; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; DEOXYCYTIDINE; HUMANS; PANCREATIC NEOPLASMS; SURVIVAL RATE;

EID: 24144439324     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2005.02.005     Document Type: Article

References (29)

1. A. Jemal, T. Murray, E. Ward Cancer Statistics, 2005 CA Cancer J Clin 55 2005 10 30
2. H.A. Burris III, M.J. Moore, J. Anderson Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer A randomized trial J Clin Oncol 15 1997 2403 2413
3. S.R. Bramhall, J. Schulz, J. Nemunaitis A double-blind placebo-controlled, randomized study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer Br J Cancer 87 2002 161 167
4. G. Colucci, F. Giuliani, V. Gebbia Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma A prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale Cancer 94 2002 902 910
5. V. Heinemann, D. Quietzsch, F. Gieseler A phase III trial comparing gemcitabine plus cisplatin vs. gemcitabine alone in advanced pancreatic carcinoma Proc Am Soc Clin Oncol 22 2003 250 (abstr 1003)
6. M.J. Moore, J. Hamm, J. Dancey Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas A phase III trial of the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 21 2003 3296 3302
7. C.M. Rocha Lima, M.R. Green, R. Rotche Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate J Clin Oncol 22 2004 3776 3783
8. E. Van Cutsem, H. van de Velde, P. Karasek Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer J Clin Oncol 22 2004 1430 1438
9. J.D. Berlin, P. Catalano, J.P. Thomas Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma Eastern Cooperative Oncology Group Trial E2297 J Clin Oncol 20 2002 3270 3275
10. S.R. Bramhall, J. Schulz, J. Nemunaitis A double-blind placebo-controlled, randomized study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer Br J Cancer 87 2002 161 167
11. P. Cheverton, H. Friess, C. Andras Phase III results of exatecan (DX-8951f) versus gemcitabine (Gem) in chemotherapy-naïve patients with advanced pancreatic cancer (APC) Proc Am Soc Clin Oncol 23 2004 314s (abstr 4005)
12. E.M. O'Reilly, G.K. Abou-Alfa, R. Letourneau A randomized phase III trial of DX-8951f (Exatecan Mesylate: DX) and gemcitabine (GEM) vs. gemcitabine alone in advanced pancreatic cancer (APC) Proc Am Soc Clin Oncol 23 2004 315s (abstr 4006)
13. E.M. O'Reilly DX-8951f in advanced pancreatic cancer 2004 2004 Gastrointestinal Cancers Symposium. San Francisco, CA, January 22-24
14. D.A. Richards, H.L. Kindler, H. Oettle A randomized phase III study comparing gemcitabine + pemetrexed versus gemcitabine in patients with locally advanced and metastatic pancreas cancer Proc Am Soc Clin Oncol 23 2004 315s (abstr 4007)
15. C. Louvet, R. Lablanca, P. Hammel GemOx (Gemcitabine + Oxaliplatin) versus Gem (Gemcitabine) in non resectable pancreatic adenocarcinoma Final results of the GERCOR/GISCAD Intergroup Phase III Proc Am Soc Clin Oncol 23 2004 315s (abstr 4008)
16. U.S. Food and Drug Administration, Department of Health and Human Services. FDA News February 5, 2004; Consumer Drug Information - Alimta. Available at: http:/www.fda.gov/cder/consumerinfo/DRUGINFO/Alimta.htm. (accessed Nov 2, 2004)
17. K.D. Miller, J. Picus, C. Blanke Phase II study of the multi-targeted antifolate LY231514 (ALIMTA, MTA, pemetrexed disodium) in patients with advanced pancreatic cancer Ann Oncol 11 2000 101 103
18. H.L. Kindler The pemetrexed/gemcitabine combination in pancreatic cancer Cancer 95 suppl 4 2002 928 932
19. C. Louvet, T. Andre, G. Lledo Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma Final results of a GERCOR multicenter phase II study J Clin Oncol 20 2002 1512 1518
20. R. Grunewald, H. Kantarjian, M.J. Keating Pharmacologically directed design of the dose rate and schedule of 2', 2'-difluorodeoxycytidine (gemcitabine) administration in leukemia Cancer Res 50 1990 6823 6826
21. J.L. Abbruzzese, R. Grunewald, E.A. Weeks A phase I clinical, plasma, and cellular pharmacology study of gemcitabine J Clin Oncol 9 1991 491 498
22. M. Tempero, W. Plunkett, V. Ruiz Van Haperen Randomized phase II comparison of dose-intense gemcitabine Thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma J Clin Oncol 21 2003 3383 3384
23. E. Giovannetti, V. Mey, R. Danesi Synergistic cytotoxicity and pharmacogenetics of gemcitabine and pemetrexed combination in pancreatic cancer cell lines Clin Cancer Res 10 2004 2936 2943
24. R.L. Fine, W. Sherman, J. Chabot Biochemically synergistic chemotherapy for advanced pancreatic cancer (PC) Proc Am Soc Clin Oncol 21 2002 144A (abstr 575)
25. H. Frucht, P.D. Stevens, D.R. Fogelman Advances in the genetic screening, work-up, and treatment of pancreatic cancer Curr Treat Options Gastroenterol 7 2004 343 354
26. M.J. Moore, D. Goldstein, J. Hamm Erlotinib improves survival when added to gemcitabine in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG] Proc Am Soc Clin Oncol 23 2005 16S (abstr 1)
27. G.S. Sack, J. Levin, W.R. Bell Troussean syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms Clinical, pathophysiologic and therapeutic features Medicine 56 1977 1 37
28. A.A. Khorana, A. Sahni, O.D. Altand Heparin inhibition of endothelial cell proliferation and organization is dependent on molecular weight Arterioscler Thromb Vasc Biol 23 2003 2110 2115
29. K. Norrby Heparin and angiogenesis A low-molecular-weight fraction inhibits and a high-molecular-weight fraction stimulates angiogenesis systemically Haemostasis 23 suppl 1 1993 141 149